DeepMed Research

Amifostine

Generic Name: Amifostine

Brand Names: Ethyol

Drug Type: Small Molecule

Chemical Formula: C_₅H_₁₅N_₂O_₃PS

CAS Number: 20537-88-6

Unique Ingredient Identifier: ILA426L95O

Background: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.

Indication: For reduction in the cumulative renal toxicity in patients with ovarian cancer (using cisplatin) and moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.

Associated Conditions: Dry Mouth, Nephrotoxicity, Prophylaxis of Radiation proctitis

Clinical Trials

Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer

Phase 3

Completed

Conditions: Radiation Toxicity
Oral Complications
Drug/Agent Toxicity by Tissue/Organ
Lung Cancer

Interventions: Biological: filgrastim
Drug: amifostine trihydrate
Drug: carboplatin
Drug: paclitaxel
Radiation: radiation therapy

First Posted Date: 2003-11-26

Last Posted Date: 2014-11-21

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 243

Registration Number: NCT00003313

Locations: 🇺🇸
North Mississippi Medical Center/Cancer Center, Tupelo, Mississippi, United States
🇺🇸
RMH Regional Canter Center, Harrisonburg, Virginia, United States
🇺🇸
Greater Baltimore Medical Center and Cancer Center, Baltimore, Maryland, United States

and more 261 locations

Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer
Drug/Agent Toxicity by Tissue/Organ
Radiation Toxicity

Interventions: Biological: filgrastim
Drug: amifostine trihydrate
Drug: cisplatin
Drug: etoposide
Drug: paclitaxel
Drug: topotecan hydrochloride
Radiation: radiation therapy

First Posted Date: 2003-10-08

Last Posted Date: 2016-07-06

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 73

Registration Number: NCT00006012

Locations: 🇺🇸
Galesburg Cottage Hospital, Galesburg, Illinois, United States
🇺🇸
Siouxland Regional Cancer Center, Sioux City, Iowa, United States
🇺🇸
St. Elizabeth Regional Medical Center, Lincoln, Nebraska, United States

and more 81 locations

Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome

Phase 2

Conditions: Leukemia
Myelodysplastic Syndromes

First Posted Date: 2003-09-25

Last Posted Date: 2013-12-04

Lead Sponsor: ALZA

Target Recruit Count: 25

Registration Number: NCT00003827

Locations: 🇺🇸
Cancer Center and Beckman Research Institute, City of Hope, Duarte, California, United States

Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

Interventions: Biological: filgrastim
Drug: amifostine trihydrate
Drug: cisplatin
Drug: cyclophosphamide
Drug: vincristine sulfate
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy

First Posted Date: 2003-07-09

Last Posted Date: 2012-11-07

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 94

Registration Number: NCT00003211

Locations: 🇺🇸
Texas Children's Cancer Center, Houston, Texas, United States
🇦🇺
Royal Children's Hospital, Parkville, Victoria, Australia
🇦🇺
Children's Hospital at Westmead, Westmead, New South Wales, Australia

and more 1 locations

Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor

Phase 2

Completed

Conditions: Neutropenia
Sarcoma

Interventions: Biological: filgrastim
Drug: amifostine trihydrate
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: ifosfamide
Drug: topotecan hydrochloride
Drug: vincristine sulfate
Procedure: conventional surgery
Radiation: low-LET cobalt-60 gamma ray therapy
Radiation: low-LET electron therapy
Radiation: low-LET photon therapy

First Posted Date: 2003-06-18

Last Posted Date: 2013-02-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 130

Registration Number: NCT00002643

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Medical City Dallas Hospital, Dallas, Texas, United States
🇺🇸
Long Beach Memorial Medical Center, Long Beach, California, United States

and more 46 locations

Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors

Phase 1

Terminated

Conditions: Chordoma
Liver Cancer
Neuroblastoma
Retinoblastoma
Ovarian Cancer
Sarcoma
Childhood Germ Cell Tumor
Kidney Cancer
Brain and Central Nervous System Tumors

Interventions: Drug: amifostine trihydrate
Drug: busulfan
Drug: filgrastim
Drug: melphalan
Drug: thiotepa
Procedure: peripheral blood stem cell transplantation (PBSC)

First Posted Date: 2003-05-02

Last Posted Date: 2017-11-29

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 13

Registration Number: NCT00003926

Locations: 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States

Paclitaxel and Radiation Therapy Plus Chemoprotection With Amifostine in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Phase 1

Completed

Conditions: Head and Neck Cancer
Oral Complications

Interventions: Drug: amifostine trihydrate
Drug: paclitaxel
Procedure: conventional surgery
Radiation: radiation therapy

First Posted Date: 2003-04-23

Last Posted Date: 2012-12-06

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 37

Registration Number: NCT00003193

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer

Phase 3

Completed

Conditions: Gestational Trophoblastic Tumor
Neurotoxicity
Peripheral Neuropathy
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-04-09

Last Posted Date: 2013-07-09

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 100

Registration Number: NCT00058071

Locations: 🇺🇸
Rush-Copley Cancer Care Center, Aurora, Illinois, United States
🇺🇸
Elkhart General Hospital, Elkhart, Indiana, United States
🇺🇸
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States

and more 54 locations

Gemcitabine, Cisplatin, and Amifostine Following Surgery in Treating Patients With Locally Advanced Bladder Cancer

Phase 2

Completed

Conditions: Bladder Cancer
Drug/Agent Toxicity by Tissue/Organ

Interventions: Drug: amifostine trihydrate
Drug: cisplatin
Drug: gemcitabine hydrochloride
Procedure: adjuvant therapy

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 37

Registration Number: NCT00006105

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

Combination Chemotherapy With or Without Amifostine in Treating Young Patients With Liver Cancer

Phase 3

Completed

Conditions: Childhood Hepatoblastoma
Recurrent Childhood Liver Cancer
Stage I Childhood Liver Cancer

Interventions: Procedure: therapeutic conventional surgery
Drug: cisplatin
Drug: vincristine sulfate
Drug: carboplatin
Drug: fluorouracil
Drug: amifostine trihydrate

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-14

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 277

Registration Number: NCT00003994

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy